SCHEMBL4110920

SCHEMBL4110920

Cc1cc(-c2ccccc2)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc2ccn(C)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 9/20 0.52
CYP2C9 P11712 7/20 0.52
CYP2C19 P33261 7/20 0.52
ABCB1 P08183 6/20 0.52
CYP3A4 P08684 3/20 0.52
CYP2D6 P10635 3/20 0.52
KCNH2 Q12809 3/20 0.52
ABCC1 P33527 2/20 0.52
ADORA1 P30542 2/20 0.52
ABCC3 O15438 1/20 0.52
ESR1 P03372 1/20 0.52
CYP1A2 P05177 1/20 0.52
PGR P06401 1/20 0.52
CHRM2 P08172 1/20 0.52
ADRA2A P08913 1/20 0.52
CHRM1 P11229 1/20 0.52
DRD1 P21728 1/20 0.52
PTGS1 P23219 1/20 0.52
SLC6A2 P23975 1/20 0.52
OPRM1 P35372 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4111235 0.95 CYP2C9 (0.54) ABCG2CYP2C9CYP2C19ABCB1CYP3A4
SCHEMBL4106754 0.93 CYP2C9 (0.50) ABCG2CYP2C9CYP2C19ABCB1CYP3A4
SCHEMBL10195908 0.93 CYP2C9 (0.52) ABCG2CYP2C9CYP2C19ABCB1CYP3A4
SCHEMBL4115999 0.92 CYP2C19 (0.51) ABCG2CYP2C9CYP2C19ABCB1CYP3A4
SCHEMBL11946759 0.92 CYP2C9 (0.51) ABCG2CYP2C9CYP2C19ABCB1CYP3A4
SCHEMBL4104303 0.91 CYP2C9 (0.48) ABCG2CYP2C9CYP2C19ABCB1CYP3A4
SCHEMBL4118621 0.91 CYP2C9 (0.55) ABCG2CYP2C9CYP2C19ABCB1CYP3A4
SCHEMBL4106157 0.91 CYP2C19 (0.51) ABCG2CYP2C9CYP2C19ABCB1CYP3A4
SCHEMBL1716248 0.90 CYP2C9 (0.62) ABCG2CYP2C9CYP2C19ABCB1CYP3A4
SCHEMBL4100879 0.90 CYP2C19 (0.51) ABCG2CYP2C9CYP2C19ABCB1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372852-B2 Purines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8372852-B2 Purines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8372852-B2 Purines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-20120277206-A1 REVERSE TRANSCRIPTASE INHIBITORS Andrea Boesciences, Inc. (US) 2012-11-01 US disclosed
US-20120277206-A1 REVERSE TRANSCRIPTASE INHIBITORS Andrea Boesciences, Inc. (US) 2012-11-01 US disclosed
US-20120277206-A1 REVERSE TRANSCRIPTASE INHIBITORS Andrea Boesciences, Inc. (US) 2012-11-01 US disclosed
EP-2220091-B1 REVERSE TRANSCRIPTASE INHIBITORS ARDEA BIOSCIENCES INC (US) 2012-07-25 EP disclosed
US-8207178-B2 Fused pyrimidines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2012-06-26 US disclosed
US-8207178-B2 Fused pyrimidines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2012-06-26 US disclosed
US-8207178-B2 Fused pyrimidines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2012-06-26 US disclosed
WO-2009079412-A2 REVERSE TRANSCRIPTASE INHIBITORS ARDEA BIOSCIENCES INC. (US) 2009-06-25 WO disclosed
US-20090162319-A1 REVERSE TRANSCRIPTASE INHIBITORS ARDEA BIOSCIENCES (US) 2009-06-25 US disclosed
US-20090162319-A1 REVERSE TRANSCRIPTASE INHIBITORS ARDEA BIOSCIENCES (US) 2009-06-25 US disclosed
US-20090162319-A1 REVERSE TRANSCRIPTASE INHIBITORS ARDEA BIOSCIENCES (US) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277206-A1 REVERSE TRANSCRIPTASE INHIBITORS POLRMT, POLR1E, TYMP ABCG2 2848/4885CYP2C9 2156/4885CYP2C19 1979/4885
US-20090162319-A1 REVERSE TRANSCRIPTASE INHIBITORS POLRMT, POLR1E, TYMP ABCG2 2848/4885CYP2C9 2156/4885CYP2C19 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.